Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2011

View Archived Issues

NICE recommends approval of Votrient as first-line therapy for kidney cancer

Studies of CGI-1746 underscore therapeutic potential of BTK inhibition in rheumatoid arthritis

Mechanism of action of darinaparsin in Hodgkin's and T-cell lymphomas clarified

FdUMP[10] is active against acute myeloid leukemia in vitro and in vivo

New target identified for treatment of psoriasis-associated skin inflammation

AMRI and Genentech enter licensing agreement for antibacterial agents

Kiadis Pharma and Hospira collaborate to develop ATIR

Vaccinex begins phase I trial of VX15/2503 in solid tumors

Spectrum Pharma submits sNDA to FDA for Fusilev in colorectal cancer

Santaris expands alliance with Pfizer for RNA-targeted medicines

Novel 3-dehydroquinate dehydratase inhibitors discovered

Fidaxomicin receives FDA orphan drug status for pediatric CDI

GSK claims new lysophospholipid S1P1 receptor agonists

Allon Therapeutics agrees on SPA for phase II/III davunetide trial in supranuclear palsy

Xoma and Servier sign agreement for anti-inflammatory candidate XOMA-052

New inhibitors of serine/threonine-protein kinase 6 discovered

Isis Pharma launches phase II program for ISIS-EIF4ERx in cancer

Takeda discloses new agonists of free fatty acid FFA1 receptor

CardioVascular BioTherapeutics presents phase II data on CVBT-141B

Bayer begins phase II trial of BAY-86-9766 and sorafenib in liver cancer

PharmaMar begins phase II trial of PM-00104 in Ewing's sarcoma

Genocea Biosciences raises funds to support vaccine development

Wyeth patents new 11-beta-HSD1 inhibitors

Alnylam reports new phase I data on RNAi therapeutic ALN-VSP

Novavax begins phase I study to evaluate RSV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...